Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis

Wenxing Yang a,d, Dongxue Zhang b,d, Zhuo Li c, Kui Zhang c,*

a Department of Physiology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
b Equipment and Material Department, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
c Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China

Received 4 April 2022; received in revised form 14 May 2022; accepted 24 May 2022
Available online 2 June 2022

KEYWORDS
COVID-19 vaccine; Serologic response; Predictors; Cancer patients; Meta-analysis

Abstract  Backgrounds: Patients with cancer presented a lower probability to obtain seroconversion after a complete course of COVID-19 vaccination. However, little was known on the factors that predict poor seroconversion in this frail population.

Methods: We searched the PubMed, EMBASE, and China National Knowledge Infrastructure databases for all articles within a range of published years from 2019 to 2022 on the predictors of response to COVID-19 vaccine in patients with cancer (last search was updated on 2st March 2022). The odds ratio corresponding to the 95% confidence interval was used to assess the outcome. The statistical heterogeneity among studies was assessed with the Q-test and I² statistics. The review was registered with PROSPERO (CRD42022315687) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Twenty cohort studies met the inclusion criteria for this study, with 5,499 patients with cancer. We found that advanced age, male patients, and metastatic disease increased negative seropositivity to COVID-19 vaccine. Immunoglobulin heavy chain variable mutation status, high concentration of Ig G, Ig M, and Ig A were correlated with seropositivity. Relating to cancer treatment strategy, anti-CD20 therapy within recent 12 months and chemotherapy were negatively correlated with seroconversion. Meta-analysis found no significant difference associated with targeted treatment, immunotherapy, and endocrine treatment.

* Corresponding author: Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, PR China.
E-mail address: cheungque@163.com (K. Zhang).

https://doi.org/10.1016/j.ejca.2022.05.031
0959-8049/© 2022 Elsevier Ltd. All rights reserved.
1. Introduction

Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world, afflicting more than 459.7 million people, resulting in more than 6 million deaths globally as of 16 March 2022, and with a mortality rate about 1.3%. The morbidity and mortality of COVID-19 were found higher in patients with cancer [1,2]. Worldwide, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020, and the global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020 [3]. It is precisely because that patients with cancer are purported to have poor COVID-19 outcomes [4–7], and recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against COVID-19 infection [8–10], disease prevention is the most effective way to contain new cases, and major medical societies fostered priority mass vaccination in this high-risk population [11,12].

For this reason, healthcare authorities should prioritise vaccinations for patients with cancer. On the basis of the clinical trials [13], considering the high morbidity and mortality from COVID-19 in patients with cancer, the benefits of vaccination are likely to far outweigh the risks of vaccine-related adverse events. However, researches [14–17] demonstrate a lower probability to obtain seroconversion after a complete course of COVID-19 vaccination, with about 6% of patients with cancer in treatment failed to develop an immune response after mRNA vaccination, as compared to only 0.2% in controls, accounting for a 30-fold higher probability [14].

Patients with cancer have an impaired immune response to COVID-19 vaccination with lower and/or lagged seroconversion rate [18,19]. The vaccination against COVID in cancer (VOICE) study aimed to reveal influences of anti-cancer treatments in response to vaccination [20], and the COVID-19 antiviral response (CAPTURE), a pan-tumour immune monitoring study, suggested a fundamental understanding of the interaction between host immunity, the virus, cancer, and anti-cancer treatments placed in the wider healthcare context in order to minimise harm and optimise cancer outcomes [21]. To propose a tailored approach to COVID-19 vaccination for patients with cancer, a thorough understanding of factors affecting on COVID-19 vaccination efficacy in patients with cancer with poor immune conditions is requisite. We conducted this meta-analysis to assess the factors that predict poor seroconversion comprehensively in order to plan better prevention strategies in this frail population.

2. Methods

We did a systematic review and meta-analysis of studies on factors affecting humoral response to COVID-19 vaccine in patients with cancer. The review was registered with PROSPERO (CRD42022315687) and reported according to PRISMA guidelines [22].

2.1. Publication search and inclusion criteria

We searched the PubMed, EMBASE, and China National Knowledge Infrastructure databases for all articles within a range of published years from 2019 to 2022 on the predictors of response to COVID-19 vaccine in patients with cancer (last search was updated on 2 March 2022). The following terms were used in this search: ‘COVID-19 vaccine’ and ‘cancer’ and ‘serologic response or seroconversion’. In order to identify the relevant publications, the references cited in the research papers were also scanned. Combining searches resulted in 51 abstracts (Fig. 1). An additional 17 studies were identified through review articles and meta-analysis, for a total of 68 studies.

We evaluated the eligible studies if all the following conditions were met: (1) evaluation of factors affecting the response to COVID-19 vaccine in patients with cancer; (2) inclusion of sufficient data or the data can be acquired from the manuscript or supplementary materials to calculate odds ratio (ORs) and 95% confidence intervals (CIs); (3) the publication was a cohort study; and (4) the study was published in English.

2.2. Data extraction

Two authors (Wenxing Yang and Dongxue Zhang) independently reviewed and extracted the data needed. Disagreements were resolved through discussion among the authors to achieve a consensus. Publications were read by Wenxing Yang in order to check original data extraction. The following information was recorded for...
each study: first author, year of publication, region, cancer type, vaccine type, vaccine dose, number of cases, and impact factors (all of the data are shown in Table 1).

2.3. Statistical analysis

The OR corresponding to the 95% CI was used to assess the outcome. The potential impact factors include age, gender, metastasis, immunoglobulin heavy chain variable region (IGHV) mutation status, IgG level, IgM level, IgA level, anti-CD20 therapy within recent 12 months, targeted therapy, chemotherapy, endocrine therapy, and immunotherapy.

The statistical heterogeneity among studies was assessed with the Q-test and $I^2$ statistics [23]. If no obvious heterogeneity, the fixed-effects model (the Mantel–Haenszel method) was used to estimate the summary OR [24]; otherwise, the random-effects model (the DerSimonian and Laird method) was used [25]. Finally, random effects models were used to calculate the OR estimates and 95% CIs of factors which associated with response to COVID-19 vaccine in patients with cancer. To explore sources of heterogeneity across studies, we did logistic meta-regression analyses. We examined the following study characteristics: publication year, region, vaccine dose, and number of cases. Publication bias was evaluated with funnel plot and Begg’s rank correlation method [26]. The statistical analyses were performed by STATA 12.0 software (Stata Corp., College Station, TX).

3. Results

3.1. Characteristics of studies

Out of a total of 68 abstracts were screened, 22 were retrieved for more detailed evaluation. The two excluded studies lacked sufficient data (shown in Fig. 1). Finally, 20 cohort studies met the inclusion criteria for this study [14,16,27–44], with 5,499 patients with cancer. All of
| Reference         | Year | Region   | Cancer type | Vaccine dose | Vaccine type | Cases | Impact factors                                                                 |
|-------------------|------|----------|-------------|--------------|--------------|-------|--------------------------------------------------------------------------------|
| Gounant V [39]    | 2022 | France   | Lung cancer | Second       | BNT162b2     | 244   | Age, gender, metastasis, target therapy, chemotherapy, immunotherapy           |
| Amatu A [14]      | 2021 | Italy    | Solid cancer| Second       | BNT162b2     | 171   | Age, gender, target therapy, chemotherapy, endocrine therapy, immunotherapy   |
| Cavanna L [31]    | 2021 | Italy    | Solid cancer| Second       | BNT162b2     | 257   | Age, gender, metastasis, target therapy, chemotherapy, immunotherapy           |
| Yasin AI [44]     | 2022 | Turkey   | Cancer      | Second       | CoronaVac    | 776   | Age, gender, metastasis, target therapy, chemotherapy, endocrine therapy, immunotherapy |
| Herishanu Y [41]  | 2022 | Israel   | CLL         | Third        | BNT162b2     | 172   | Age, gender, IGHV mutational status, IgG level, IgM level, IgA level, anti-CD20 treatment |
| Herishanu Y [35]  | 2021 | Italy    | CLL         | Second       | BNT162b2     | 167   | Age, gender, IGHV mutational status, IgG level, IgM level, IgA level, anti-CD20 treatment |
| Avivi I [28]      | 2021 | Israel   | MM          | Second       | BNT162b2     | 171   | Age, gender                                                                    |
| Bagacean C [38]   | 2022 | France   | CLL         | Second       | BNT162b2 or mRNA-1273 | 530   | Age                                                                            |
| Di Noia V [33]    | 2021 | Italy    | Cancer      | Second       | BNT162b2     | 816   | Age, gender, target therapy, chemotherapy, immunotherapy                       |
| Addeo A [27]      | 2021 | USA      | Cancer      | Second       | BNT162b2 or mRNA-1273 | 131   | Age, gender, target therapy, chemotherapy, endocrine therapy, immunotherapy   |
| Pimpinelli F [36] | 2021 | Italy    | MM and MPM  | Second       | BNT162b2     | 92    | Age, gender                                                                    |
| Haydu JE [40]     | 2022 | USA      | CLL         | Second       | SARS-CoV-2 and PCV13 vaccines | 30    | Age, IGHV mutational status, IgG level                                         |
| Buttiron Webber T [30] | 2021 | Italy    | Cancer      | Second       | BNT162b2     | 291   | Age, gender, target therapy, chemotherapy, endocrine therapy, immunotherapy   |
| Benjamini O [29]  | 2021 | Israel   | CLL         | Second       | BNT162b2     | 373   | Age, gender, IGHV mutational status, IgG level, IgM level, IgA level, anti-CD20 treatment |
| Grinshpun A [34]  | 2021 | Israel   | Cancer      | Second       | BNT162b2     | 202   | Age, gender, metastasis, target therapy, chemotherapy, endocrine therapy, immunotherapy |
| Marasco V [42]    | 2022 | Italy    | LM          | First        | BNT162b2     | 263   | Age, IgG level, IgM level, IgA level                                           |
| Reimann P [43]    | 2022 | Austria  | Cancer      | Third        | BNT162b2     | 29    | Gender                                                                         |
| Goshen-Lago T [16] | 2021 | Israel   | Cancer      | Second       | BNT162b2     | 218   | Gender, metastasis, target therapy, chemotherapy, immunotherapy               |
| Debie Y [32]      | 2021 | Belgium  | Cancer      | Third        | BNT162b2     | 200   | Target therapy, chemotherapy, immunotherapy                                  |
| Ruggeri EM [37]   | 2021 | Italy    | Cancer      | Second       | BNT162b2     | 366   | Target therapy, chemotherapy, endocrine therapy, immunotherapy               |

CLL, chronic lymphocytic leukaemia; MM, multiple myeloma; MPM, myeloproliferative malignancies; LM, lymphoid malignancies.
which used a historical cohort design, with seven countries were represented. Of all the studies, one in the United States of America (USA) vaccinated with SARS-CoV-2 and PCV13 vaccines [40], one in Turkey used Corona Vaccine [44], one in USA [27] and one in France [38] underwent BNT162b2 or mRNA-1273, all the others inoculated BNT162b2. The details of the selected studies were listed in Table 1.

3.2. Quantitative synthesis

A summary of the findings from included studies is shown in Table 2, Fig. 2 and Fig. 3. Sixteen studies [14,27–31,33–36,38–42,44] with 4,686 patients with cancer reported on the effect of age. Meta-analysis found increased risk of non-response to COVID-19 vaccine in patients with cancer with advanced age (OR = 1.29, 95% CI = 1.11–1.50, $I^2 = 71.1\%$). On the basis of 16 studies [14,16,27–31,33,34,36,39,41–44] with 4,373 patients with cancer, male patients seem to react negative to COVID-19 vaccine (OR = 1.34, 95% CI = 1.13–1.58, $I^2 = 0\%$). Five studies [16,31,34,39,44] including 1,697 patients with solid tumours reported on the effect of metastatic disease. Meta-analysis found that metastatic disease was negatively correlated with seropositivity (OR = 1.61, 95% CI = 1.04–2.49, $I^2 = 53.1\%$).

IGHV mutational status was reported in four studies [29,35,40,41] including 742 patients with haematologic malignancies, Ig G level in five studies [29,35,40–42] including 1,005 patients with haematologic malignancies, Ig M and Ig A level in four studies [29,35,41,42] including 975 patients with haematologic malignancies. IGHV mutated status, high concentration of Ig G, Ig M, and Ig A were positively correlated with seropositivity (OR = 0.52, 95% CI = 0.28–0.98, $I^2 = 37.4\%$ for IGHV mutational status, OR = 0.43, 95% CI = 0.31–0.59, $I^2 = 0\%$ for Ig G, OR = 0.42, 95% CI = 0.22–0.81, $I^2 = 73.5\%$ for Ig M, OR = 0.40, 95% CI = 0.26–0.61, $I^2 = 45.1\%$ for Ig A).

Quantitative synthesis was possible for therapeutic method including targeted treatment, chemotherapy, endocrine treatment, and immunotherapy in patients with solid tumours, and anti-CD20 therapy within recent 12 months in patients with haematologic malignancies. Eleven studies [14,16,27,30–34,37,39,44] were reported on target treatment, 11 studies [14,16,27,30–34,37,39,44] were reported on chemotherapy, six studies [14,27,30,34,37,44] were reported on endocrine treatment, 11 studies [14,16,27,30–34,37,39,44] were reported on immunotherapy, and three studies [29,35,41] were reported on anti-CD20 treatment. Meta-analytical summary of the available studies found that anti-CD20 treatment was positively correlated with seropositivity (OR = 0.37, 95% CI = 0.17–0.78, $I^2 = 50.8\%$). On the contrary, chemotherapy was negatively correlated with seropositivity (OR = 2.79, 95% CI = 1.84–4.23, $I^2 = 33.9\%$). Meta-analysis found no significant difference associated with targeted treatment, immunotherapy, and endocrine treatment.

The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, and the omission of any study made no statistically reliable. Begg’s test was performed to evaluate the publication bias of selected literatures. No evidence of publication bias in our study was observed.

4. Discussion

This systematic review summarises the available global data of the effects of predictors on poor serologic response to COVID-19 vaccine in patients with cancer.
during the COVID-19 pandemic. We found that advanced age, male patients, and metastatic disease increased negative seroconversion to COVID-19 vaccine. IGHV mutated status, high concentration of Ig G, Ig M, and Ig A were correlated with seropositivity in patients with haematologic malignancies. Relating to cancer treatment strategy, anti-CD20 therapy within recent 12 months and chemotherapy were negatively correlated with seroconversion. Meta-analysis found no significant difference associated with target treatment, immunotherapy, and endocrine treatment.

There were various technology platforms for the development of COVID-19 vaccines, including whole virus vaccines, nucleic acid vaccines, protein subunit vaccines, and recombinant vaccines [45–51]. In the present meta-analysis, one study in USA vaccinated with SARS-CoV-2 [40], one in Turkey used Corona Vaccine [44], one in USA [27] and one in France [38] underwent BNT162b2 or mRNA-1273; all the others inoculated BNT162b2. Although seroconversion rates after COVID-19 vaccination were significantly lower in patients with cancer [18,19,52], no new immune-related side-effects or exacerbation of existing immune-related side-effects were observed [53]. Thus, COVID-19 vaccine guidance suggested that continued quality oncological care requires patients with cancer to be prioritised for COVID-19 vaccination, where authorised or approved [13].

The immune response to the COVID-19 involves innate immune activation and antigen-specific responses of B and T cells [54]. Serological and immunological tests are primarily applied for population-based seroprevalence studies to evaluate the effectiveness of COVID-19 control measures and increase our understanding of the immunology behind COVID-19 vaccination [55], post vaccination testing of antibody response is an important and feasible tool for following people after vaccination [56].

Patients with cancer may have poor general condition than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments [57,58]. Furthermore, vaccination is less effective at old than at young age with a statistically significant relationship between the age and level of anti the receptor-binding domain IgG after first dose of vaccine administration [56]. The present study found advanced age with increased negative seroconversion to COVID-19 vaccine may due to the unresponsiveness of immune system at older age. Females develop higher antibody responses to vaccines than males [59]. After vaccination, protective antibody responses can be twice as high in adult females than in males [60]. Measures of cell-mediated immunity following vaccination are also higher in females than in males for some vaccines [61,62]. In the patients with cancer, females seem to response positive to COVID-19 vaccine.

Patients with cancer can be immunocompromised of vaccines due to a multitude of factors, such as the patient condition, underlying malignancy itself, coupled with damage to the organs directly or indirectly involved with bone marrow suppressive effects of cytotoxic
chemotherapy, and prior or ongoing treatments with a high degree of immunosuppressive effects [63]. While patients with cancer clearly represent a highly susceptible group with a strong and immediate need to be protected by available, effective vaccines. It is noteworthy that active cancer therapy modulates the immune response to vaccines depending on the type of treatment [64]. It has not been clearly revealed whether
it would be better to continue or initiate therapy during the COVID-19 pandemic, especially when they receive the vaccine. The present meta-analysis tried to find the optimum seroconversion among patients receiving distinct cancer therapeutics. The results indicated that anti-CD20 therapy within recent 12 months and chemotherapy were negatively correlated with seroconversion. The underlying reason could be that cytotoxic agents may directly or indirectly damage DNA molecules. Furthermore, our results suggested that the targeted treatment, immunotherapy, and endocrine treatment seem not to affect the seroconversion of COVID-19 vaccine.

A few limitations of our study should be considered. Although we did not observe significant publication bias, publication bias is possible in any meta-analysis. Furthermore, although most the studies inoculated BNT162b2, several other studies vaccinated with SARS-CoV-2, Corona Vaccine, or mRNA-1273 may substantially affect the result. Moreover, it remains uncertain how serological and immunological parameters are precisely correlated with the extent of protective immunity [55]; serological diagnostics may ignore the T-cell responses by vaccination. Finally, due to the limited available researches, different cancer types may respond differently to COVID-19 vaccine.

In conclusion, our meta-analysis assessed the factors that predict poor seroconversion in order to propose a tailored approach to COVID-19 vaccination in this frail population. The results proposed that enhanced vaccination strategies would be beneficial for the special patients such as advanced male, or patients receiving active chemotherapy, and carefully prevention should be emphasised even after a complete course of vaccination.

Funding

The present study received no funding support.

Author contribution

Kui Zhang contributes to the Conceptualisation; Wenxing Yang and Dongxue Zhang contribute to Data curation and Project administration; Zhuo Li contributes to Software and Writing - review and editing; Wenxing Yang and Kui Zhang contribute to Writing - original draft.

Conflict of interest statement

No conflicts of interests to declare.

References

[1] Tian Y, Qiu X, Wang C, Zhao J, Jiang X, Niu W, et al. Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. Int J Cancer 2021;148:363–74.
[2] Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer (Oxford, England : 1990) 2020;139:43–50.
[3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 2021;71:209–49.
[4] Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOCOV-19). Eur J Cancer (Oxford, England : 1990) 2020;141:62–81.
[5] Whisenant JG, Trama A, Torri V, De Toma A, Viscardi G, Cortellini A, et al. TERAVOLT: thoracic cancers international COVID-19 collaboration. Cancer Cell 2020;37:742–5.
[6] Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020;21:914–22.
[7] Lee HL, Cazier JB, Angelis V, Arnold R, Bish V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England) 2020;395:1919–26.
[8] Drozdžal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyciński J, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 2021;59:100794.
[9] Kashour Z, Kashour T, Gerberi D, Tleyjeh IM. Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Clinical and translational science 2021;14:1101–12.
[10] Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect of hydroxychloroquine on clinical status at 14 Days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA 2020;324:2165–76.
[11] Curigliano G, Barjere S, Cervantes A, Garassino MC, Garrido P, Girard N, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol : Official Journal of the European Society for Medical Oncology 2020;31:1320–35.
[12] Corti C, Ciminì E, Tarantino P, Pravettoni G, Eggermont AMM, Delaloge S, et al. SARS-CoV-2 vaccines for cancer patients: a call to action. Eur J Cancer (Oxford, England : 1990) 2020;148:316–27.
[13] Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 2021;18:313–9.
[14] Amatu A, Pani A, Patelli G, Gagliardi OM, Lopardo M, Piscazzi D, et al. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. Eur J Cancer (Oxford, England : 1990) 2021;163:16–25.
[15] Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22:765–78.
[16] Goshen-Lago T, Waldhorn I, Holland R, Sewarcworth-Cohen M, Reiner-Benaia A, Shachor-Meyouhas Y, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol 2021;7:1507–13.
[50] Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol 2016;41:47–54.

[51] Capone S, D’Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccine 2013;12:379–93.

[52] Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ (Clinical Research ed) 2022;376:e068632.

[53] Waisseginrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol 2021;22:581–3.

[54] Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020;26:453–5.

[55] Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C. How to interpret and use COVID-19 serology and immunology tests. Clinical Microbiol Infection : The Official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021;27:981–6.

[56] Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol Spectr 2021;9:e0034121.

[57] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–7.

[58] Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Ser A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol 2021;7:1133–40.

[59] Pulcini C, Massin S, Launay O, Verger P. Factors associated with vaccination for hepatitis B, pertussis, seasonal and pandemic influenza among French general practitioners: a 2010 survey. Vaccine 2013;31:3943–9.

[60] Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010;10:338–49.

[61] Umlauf BJ, Haralambieva IH, Ovsyannikova IG, Kennedy RB, Pankratz VS, Jacobson RM, et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. Viral Immunol 2012;25:29–36.

[62] Zhang X, Castelli FA, Zhu X, Wu M, Maille`re B, BenMohamed L. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clinical and vaccine immunology. CVI 2008;15:1436–49.

[63] Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39:1081–1090.e2.

[64] Rousseau B, Loulergue P, Mir O, Krivine A, Kotti S, Vel E, et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol : Official Journal of the European Society for Medical Oncology 2012;23:450–7.